To elucidate the pathogenesis of thyroid gland hypervascu-
Introduction
In patients with Graves' disease, the thyroid gland is hypervascular, and a venous hum is usually heard (1) . Although these phenomena are pathognomonic clinical features of Graves' disease, their pathogenesis remains to be elucidated.
Recently, a number of in vivo angiogenesis factors have been reported (2, 3) . However, TGF-a, TGF-3, TNF-a, angiogenin, and PGE have little or no mitogenic effect on cultured endothelial cells in vitro. Although acidic fibroblast growth factor, basic fibroblast growth factor (bFGF), and platelet-derived endothelial growth factor can stimulate both vascular endothelial growth in vitro and angiogenesis in vivo, they lack a signal peptide, implying that these factors may become available to their target cells only after cell death (2, 3) .
In contrast, vascular endothelial growth factor (VEGF),' a secretable factor that preferentially stimulates the proliferation of endothelial cells, does have a signal peptide, implying that it is a physiological angiogenesis factor (4, 5) . Recently, a receptor flt, fins-like tyrosine kinase (now designated as fit-i) and an flt-related kinase KDR/fik-1 (6, 7) , have been identified as the receptors for VEGF (7, 8) . The binding sites for VEGF are localized exclusively on endothelial cells (9) , and binding to the receptor is followed by proliferation of the cells (3) (4) (5) (6) (7) (8) (9) (10) (11) . On the assumption that VEGF from thyroid parenchymal cells and Flt family on endothelial cells might be involved in the thyroid gland hypervascularity seen in patients with Graves' disease, we studied whether the gene for VEGF is expressed in human thyroid cells, and whether the levels of VEGF mRNA are regulated by thyrotropic factors, using human thyroid follicles in suspension culture, in which thyroid follicles incorporate 125I and secrete de novo-synthesized thyroid hormones into the culture medium in response to thyroid-stimulating hormone (TSH) and human chorionic gonadotropin (12) (13) (14) . Furthermore, we studied the in vivo expression of VEGF andflt family mRNAs in thiouracil-fed rats, in which thyroid epithelial and endothelial cell proliferation has been examined in detail histologically (15) .
Methods
Sources of materials and Graves' IgG. Culture media (F-12, RPMI 1640) were obtained from Gibco Laboratories, Grand Island, NY. FCS was obtained from Filtron Ltd., Brooklyn, Australia. Collagenase (type IV), bovine TSH, thiouracil, A23187, dibutyryl cAMP, H7, and tumorpromoting phorbol ester (12-O-tetradecanoyl-phorbol-13-acetate, TPA)
were obtained from Sigma Chemical Co., St. Louis, MO. IgG from patients with untreated Graves' disease (Graves' IgG) was obtained, as described previously ( 14) . Usually, 6 ml serum was dialyzed against 1 . Abbreviations used in this paper: flt, fins-like tyrosine kinase or VEGF receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
TPA, 12-O-tetradecanoylphorbol-13-acetate; TSH, thyroid-stimulating hormone; TSI, thyroid-stimulating Ig; VEGF, vascular endothelial growth factor. 10 mM Tris-HCl buffer (pH 7.4) and applied to a protein A-Sepharose column. After eluting with 0.1 M glycine-HCl buffer (pH 3.0), the eluate was immediately neutralized with 1 N NaOH and then extensively dialyzed against 0.9% NaCl solution. Finally, the eluates were dialyzed against culture medium and sterilized by filtering through a 0.45-eum filter (Millipore, Corp., Bedford, MA). The samples were stored at 40C.
Preparation ofthyroidfollicles. Patients with Graves' disease scheduled for surgery were given iodine supplements for 8-14 d before surgery. Informed consent was obtained from all subjects. The thyroid tissue ( 15-30 g ) obtained by subtotal thyroidectomy from these patients was minced with scissors into small pieces (3 X 3 X 3 mm) in 10 ml icecold Ca2", Mg2"-free HBSS. The dissected thyroid tissue was filtered through nylon mesh (80 mesh) and washed with 10 ml HBSS. The dissected thyroid tissues were digested with 0.3 mg/ml collagenase (type IV) and 5 mg/ml dispase (Godo Shusei Co., Tokyo, Japan) in HBSS at 320C for 30 min, and thyroid follicles were obtained as described previously (12, 13) .
The thyroid follicles were cultured in 1 ml F-12/RPMI 1640 (1:1) medium supplemented with various concentrations of FCS (0-10%) in 24-multiwell dishes (-300 follicles/2-cm2 well). In several experiments, the follicles were cultured in serum-free F-12/RPMI 1640 (1:1) medium supplemented with BSA (2 mg/ml), bovine insulin (5 /Lg/ml), hydrocortisone (10-8 M), bovine transferrin (5 pg/ml), and NaI (10-8 M), as described previously (13, 14) . The dishes were pretreated with agarose to prevent attachment of thyroid follicles (16) .
When thyroid hormonogenesis was studied, 125I ( 15,000 cpm) was added after culturing for 5 (17) .
In vitro studies of VEGF mRNA expression in human thyroid follicles. To study the regulation of VEGF mRNA expression in thyroid follicles, -30,000 follicles were cultured in 10 ml F-12/RPMI 1640 medium supplemented with 1% FCS for 3 d. Then, the thyroid follicles were treated with insulin, TPA, TSH, or IgG from patients with active Graves' disease for 0-3 d, as described in each experiment. In some experiments, thyroid follicles were cultured in medium containing various concentrations of FCS (0-10%) or serum-free F-12/RPMI 1640 medium supplemented with insulin and TSH (10 pU/ml). Usually, 10-cm dishes were pretreated with agarose to culture thyroid follicles in suspension. After appropriate culture periods, the thyroid follicles were centrifuged and total RNA was extracted as reported previously (18) .
In several experiments, thyroid follicles were cultured in agaroseuntreated dishes. The thyroid follicles became attached to the dishes on the following day and became flattened on days [5] [6] [7] were anesthetized with ether. After blood had been taken from the abdominal vein, the thyroid gland was removed from the trachea and dissected with scissors in an ice-cold denaturing solution (4 M guanidinium thiocyanate) (19) . Then thyroid pieces were homogenized using a homogenizer with a Teflon pestle. RNA from four to six rats was combined and used for Northern blot analysis.
Serum T3 and T4 were measured using immunoradiometric assay kits (Eiken Immunochemical Co., Tokyo, Japan). Rat TSH was measured using a rat TSH l25I assay kit (PRA.548; Amersham Life Science, Tokyo, Japan). To avoid interassay variance, all samples were determined simultaneously.
Northern blot analysis of mRNAs for VEGF, flt-i, and KDR/flk-J.
Total cellular RNA was isolated by guanidinium thiocyanate and phenol extraction according to the method of Chomczynski and Sacchi (19) . 10 pg of total RNA was electrophoresed on 1% agarose-formaldehyde gels containing ethidium bromide. RNA samples were transferred onto nylon membranes and then hybridized with human VEGF cDNA spanning nucleotide 0.6 kb (6, 20, 21) , rat VEGF 0.5-kb cDNA, rat flt-i 1.2-kb cDNA, or rat KDR/flk-J 1.2-kb cDNA (21) SDS at 550C and exposed to X-omat film (Eastman Kodak, Rochester, NY) with an intensifying screen at -700C. For comparison of RNA loading, the filters were rehybridized with 32P-labeled human /3-actin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA (supplied by Y. Murata, Research Institute for Environmental Medicine, Nagoya University, Nagoya, Japan) (22), as described previously (18) .
Statistical analysis. Statistical analysis was performed by Student's t test when two comparisons were made. Differences were considered significant at P < 0.05.
Results
Effects of TSH, Graves' IgG, and FCS on thyroid function in cultured human thyroid follicles. As reported previously (12, 13) , bTSH stimulated human thyroid follicles to incorporate 1251I and release organic 1251 into the culture medium in a concentration-dependent manner ( Fig. 1, left) . The minimal and maximal stimulatory effects of bTSH were obtained at 0.1 and 10 MU/ml, respectively. Graves' IgG also stimulated thyroid function in a dosedependent manner (Fig. 1, right) . The IgG was purified from 6 ml serum and reconstituted in 6 ml culture medium. It stimulated thyroid function at 20 pl/ml and produced a strong stimulation at 300 pl/ml, whereas IgG obtained from normal subjects had no effect ( Fig. 1, middle) .
When thyroid follicles were cultured in medium containing various concentrations of FCS, TSH-induced thyroid function was impaired in a concentration-dependent manner (Fig. 2) . TSH stimulated thyroid function maximally in serum-free medium supplemented with 0.2% BSA. Thyroid follicles cultured with FCS at low concentration (1%) responded to bTSH but lost their responsiveness to TSH at higher concentrations (2.0-10%). Therefore, subsequent experiments were usually performed in medium containing 1% FCS or serum-free medium supplemented with 0.2% BSA.
VEGF (.) were counted. Data are means of quadruplicate cultures. * P < 0.05, * *P < 0.01, *** P < 0.001.
depressed. VEGF mRNA induced by insulin (0.2 ig/ml) was increased maximally at 2-3 h (Fig. 4, lower panel) .
Basal VEGF concentration in the medium conditioned by thyroid follicles for 3 d was 4.4±1.2 ng/ml (n = 3, mean±SD). Consistent with the mRNA level, treatment of thyroid follicles with insulin for 3 d increased the level of immunoreactive VEGF in the conditioned medium in a biphasic manner (insulin 0.2 pg/ml, VEGF 7.8 ng/ml; 1 ug/ml, 14.8 ng/ml; 5 jug/ml, 8 .0 ng/ml; 25 (Fig. 5, upper panel) , and the TPA-induced VEGF mRNA expression was increased maximally at 2-4 h incubation (Fig.  5, lower panel) (Fig. 6 ).
Effect ofprotein kinase A stimulators on VEGF mRNA expression. When thyroid follicles were cultured in medium supplemented with bTSH (10 1LU/ml) and various concentrations of FCS for the first 3 d, bTSH markedly stimulated VEGF mRNA expression at lower FCS concentrations (0.5-2%), but the stimulatory effect of bTSH was abolished at higher FCS concentrations (5%) (Fig. 7, upper panel) . Therefore, subsequent experiments were performed using thyroid follicles cultured with 1% FCS or serum-free medium supplemented with 0.2% BSA and insulin and/or TSH. After preculture of thyroid follicles in serum-free medium without TSH for 3 d, time-course studies revealed that the stimulatory effect of bTSH on VEGF mRNA expression was not distinctly evident within 1-6 h at physiological concentrations (1-100 /U/ml), although in two of six experiments, bTSH stimulated VEGF mRNA expression slightly at 2 h of incubation. However, when thyroid follicles were cultured with bTSH in the presence of insulin for 1-3 d, TSH stimulated VEGF mRNA expression in a concentration-dependent manner (Fig.  7, lower panel) .
This was also the case with IgG obtained from serum of patients with Graves' disease. Graves' IgG stimulated VEGF mRNA in human thyroid follicles cultured for 2 d (Fig. 8) .
Dibutyryl cAMP also mimicked the effect of TSH and Graves' IgG, increasing VEGF mRNA expression at 0.05-1 mM (Fig. 9) , at which concentration thyroid hormonogenesis was substantially stimulated, as described previously (14) .
When thyroid follicles were cultured in medium supplemented with 1% FCS, bTSH (100 ,U/ml), and H7 (20 MM) for 3 d, the TSH-induced expression of VEGF mRNA was substantially inhibited by H7 (Fig. 10) , suggesting that-TSH stimulates VEGF mRNA expression at least partly through protein kinase C pathway.
Expression of flt-i in cultured thyroid follicles. Thyroid Figure 8 . 6 .6±2.7 ng/ml, n = 5, means+SD), accompanied by enlargement of the thyroid glands. However, the thyroid glands were not weighed to facilitate rapid preparation of the RNA. Consistent with the in vitro findings, VEGF mRNA was expressed in the thyroid gland of control rats. VEGF mRNA expression increased to a greater extent on days 3-7, then decreased to the control level by day 14 (Fig. 12 A) . As expected, thyroid glands of control rats expressed mRNA of VEGF receptors, flt-I and its related gene KDR/flk-i. Interestingly, both flt-i and KDR/flk-I mRNAs were also increased on days 3-7, and decreased gradually to the control level on days [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] (Fig. 12, B and C) . The response of KDR/flk-i was slightly slower than that of flt-i and highest at day 7. 
Discussion
It has been proposed from in vivo studies that thyroid angiogenesis during thyroid enlargement may be due to paracrine mitogenic factors released by epithelial thyroid cells: angiogenesis factor(s) may be produced within the thyroid gland and diffuse into the blood vessels, causing mitosis of capillary endothelial cells (15, (23) (24) (25) . Using human thyroid follicles in suspension culture, which incorporate 1251 and secrete 125I-T4 and 1251-T3 into the medium in response to TSH and Graves' IgG, we demonstrated that both thyrotropic factors increased the level of VEGF mRNA in a time-and dose-dependent manner. Since VEGF is a secretable angiogenesis factor capable of specifically stimulating the proliferation of endothelial cells (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , it is reasonable to speculate that VEGF, produced in response to Figure 11 . Expression offlt-i mRNA in human placenta and cultured human thyroid follicles. Human thyroid follicles were cultured in serumfree medium supplemented with 0.2% BSA, bTSH (10 /U/ml), and insulin (1 jig/ml) for 3 d. Then, total RNA was prepared as described in Methods. mRNA was prepared from human placenta (6) . filter was sequentially P-Actin~l hybridized with these probes after removal of the previous probe. After hybridization with each probe at 1 X 106 cpm/ml, the filter was washed and exposed to x-ray film (Fuji Photo Film Co., Tokyo, Japan) for 4 TSH receptor stimulators, is responsible for proliferation of endothelial cells that surround thyroid follicles, leading to enlargement of blood vessels.
Indeed, Greil et al. (26) have reported that porcine thyroid follicles produce an endothelial cell growth factor with a mol wt of -15,000, which binds to heparin-Sepharose. Although the thyroid gland contains bFGF (27) , the protein lacks a signal peptide, suggesting that FGF or FGF-related angiogenesis factors become active only when cells are damaged or destroyed. In contrast, our in vitro findings suggest that human thyroid follicles produce VEGF mRNA in response to various factors (insulin, protein kinase A and C activators) and secrete immunoreactive VEGF into the culture medium, suggesting that VEGF is the most likely candidate for the angiogenesis factor produced in the thyroid gland. At this moment, however, we cannot completely rule out a minor possibility that the antibodies other than anti-TSH-receptor antibody in Graves' IgG also contribute in a part to this process.
Previously, light-and electron-microscopic studies by Wollman et al. (15, (23) (24) (25) (15) .
At the present time, the regulatory mechanism of VEGF expression in endocrine tissues is poorly understood. We have demonstrated that treatment of human thyroid follicles with TPA and a calcium ionophore (A23187) readily (within [2] [3] [4] h) induces a significant increase in VEGF mRNA, suggesting that VEGF mRNA expression is regulated by a protein kinase C-mediated signal transduction pathway, as reported in preadipocytes and vascular smooth muscle cells (32, 33) . Furthermore, we have demonstrated that dibutyryl cAMP, TSH, and Graves' IgG also induced VEGF mRNA expression, suggesting that both thyrotropic factors stimulate the expression of VEGF mRNA at least in part by the cAMP-dependent protein kinase A pathway. Analogous findings have also been reported for PTH in osteoblast-like cells (34) . Since TSH and Graves' IgG stimulate both the protein kinase A and protein kinase C pathways (35) (36) (37) (38) (39) , it is reasonable to speculate that TSH as well as Graves' IgG stimulates VEGF mRNA expression by acting on TSH receptors through both pathways. It is likely that VEGF, synthesized in thyrocytes in response to TSH or Graves' IgG, is secreted and binds to FMt receptors on endothelial cells, thus stimulating endothelial cell proliferation and leading to hypervascularity of thyroid glands in patients with Graves' disease. Other physiological stimuli that increase VEGF mRNA are estrogen in the uterus (39) , hypoxia in cultured cells (40) , PGE, and 1,25 (OH)2D3 in osteoblast-like cells (34, 41) .
Interestingly, the stimulatory effect of TSH on VEGF mRNA expression was abolished when thyroid follicles were cultured in medium supplemented with a high FCS concentration (5-10%), in which thyroid follicles were not capable of synthesizing thyroid hormone in response to TSH. These findings are consistent with those in the ovary, testis, and adrenal glands, in which all cell types expressing VEGF mRNA are steroidogenic and/or steroid responsive (42) , suggesting that hormonogenesis and angiogenesis in endocrine tissues are closely regulated.
Finally, it should be pointed out that in the thyroid gland of patients with Graves' disease, lymphatic fluid is produced profusely and flows into the retroorbital region (43) . This phenomenon may be due partly to overproduction of VEGF in the thyroid, since the angiogenesis factor is also a strong vascular permeability factor (44) (45) (46) .
In summary, we have demonstrated for the first time that thyroid parenchymal cells of the thyroid gland express VEGF mRNA but not fit mRNA, and that VEGF mRNA expression is stimulated by TSH and Graves' IgG, via the protein kinase A and C pathways. We have also shown that VEGF and flt mRNA expression is increased in the enlarged thyroid gland of thiouracil-fed rats. These in vitro and in vivo findings may account at least in part for the hypervascularity of the thyroid glands seen in patients with Graves' disease.
